nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylphenidate—Photosensitivity reaction—Doxorubicin—bone cancer	0.00124	0.00124	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Epirubicin—bone cancer	0.00124	0.00124	CcSEcCtD
Methylphenidate—Weight increased—Doxorubicin—bone cancer	0.00123	0.00123	CcSEcCtD
Methylphenidate—Epistaxis—Epirubicin—bone cancer	0.00123	0.00123	CcSEcCtD
Methylphenidate—Urethral disorder—Methotrexate—bone cancer	0.00123	0.00123	CcSEcCtD
Methylphenidate—Weight decreased—Doxorubicin—bone cancer	0.00123	0.00123	CcSEcCtD
Methylphenidate—Sinusitis—Epirubicin—bone cancer	0.00123	0.00123	CcSEcCtD
Methylphenidate—Pneumonia—Doxorubicin—bone cancer	0.00122	0.00122	CcSEcCtD
Methylphenidate—Infestation—Doxorubicin—bone cancer	0.00121	0.00121	CcSEcCtD
Methylphenidate—Infestation NOS—Doxorubicin—bone cancer	0.00121	0.00121	CcSEcCtD
Methylphenidate—Drowsiness—Doxorubicin—bone cancer	0.00121	0.00121	CcSEcCtD
Methylphenidate—Visual impairment—Methotrexate—bone cancer	0.00121	0.00121	CcSEcCtD
Methylphenidate—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.0012	0.0012	CcSEcCtD
Methylphenidate—Hypersensitivity—Cisplatin—bone cancer	0.0012	0.0012	CcSEcCtD
Methylphenidate—Bradycardia—Epirubicin—bone cancer	0.00119	0.00119	CcSEcCtD
Methylphenidate—Erythema multiforme—Methotrexate—bone cancer	0.00119	0.00119	CcSEcCtD
Methylphenidate—Haemoglobin—Epirubicin—bone cancer	0.00118	0.00118	CcSEcCtD
Methylphenidate—Rhinitis—Epirubicin—bone cancer	0.00118	0.00118	CcSEcCtD
Methylphenidate—Conjunctivitis—Doxorubicin—bone cancer	0.00118	0.00118	CcSEcCtD
Methylphenidate—Haemorrhage—Epirubicin—bone cancer	0.00117	0.00117	CcSEcCtD
Methylphenidate—Eye disorder—Methotrexate—bone cancer	0.00117	0.00117	CcSEcCtD
Methylphenidate—Asthenia—Cisplatin—bone cancer	0.00116	0.00116	CcSEcCtD
Methylphenidate—Pharyngitis—Epirubicin—bone cancer	0.00116	0.00116	CcSEcCtD
Methylphenidate—Cardiac disorder—Methotrexate—bone cancer	0.00116	0.00116	CcSEcCtD
Methylphenidate—Sweating—Doxorubicin—bone cancer	0.00116	0.00116	CcSEcCtD
Methylphenidate—Urinary tract disorder—Epirubicin—bone cancer	0.00116	0.00116	CcSEcCtD
Methylphenidate—Haematuria—Doxorubicin—bone cancer	0.00115	0.00115	CcSEcCtD
Methylphenidate—Connective tissue disorder—Epirubicin—bone cancer	0.00115	0.00115	CcSEcCtD
Methylphenidate—Urethral disorder—Epirubicin—bone cancer	0.00115	0.00115	CcSEcCtD
Methylphenidate—Hepatobiliary disease—Doxorubicin—bone cancer	0.00114	0.00114	CcSEcCtD
Methylphenidate—Epistaxis—Doxorubicin—bone cancer	0.00114	0.00114	CcSEcCtD
Methylphenidate—Angiopathy—Methotrexate—bone cancer	0.00114	0.00114	CcSEcCtD
Methylphenidate—Sinusitis—Doxorubicin—bone cancer	0.00113	0.00113	CcSEcCtD
Methylphenidate—Immune system disorder—Methotrexate—bone cancer	0.00113	0.00113	CcSEcCtD
Methylphenidate—Visual impairment—Epirubicin—bone cancer	0.00113	0.00113	CcSEcCtD
Methylphenidate—Mediastinal disorder—Methotrexate—bone cancer	0.00113	0.00113	CcSEcCtD
Methylphenidate—Chills—Methotrexate—bone cancer	0.00112	0.00112	CcSEcCtD
Methylphenidate—Diarrhoea—Cisplatin—bone cancer	0.00111	0.00111	CcSEcCtD
Methylphenidate—Erythema multiforme—Epirubicin—bone cancer	0.00111	0.00111	CcSEcCtD
Methylphenidate—Alopecia—Methotrexate—bone cancer	0.00111	0.00111	CcSEcCtD
Methylphenidate—Bradycardia—Doxorubicin—bone cancer	0.0011	0.0011	CcSEcCtD
Methylphenidate—Mental disorder—Methotrexate—bone cancer	0.0011	0.0011	CcSEcCtD
Methylphenidate—Eye disorder—Epirubicin—bone cancer	0.0011	0.0011	CcSEcCtD
Methylphenidate—Erythema—Methotrexate—bone cancer	0.00109	0.00109	CcSEcCtD
Methylphenidate—Malnutrition—Methotrexate—bone cancer	0.00109	0.00109	CcSEcCtD
Methylphenidate—Haemoglobin—Doxorubicin—bone cancer	0.00109	0.00109	CcSEcCtD
Methylphenidate—Flushing—Epirubicin—bone cancer	0.00109	0.00109	CcSEcCtD
Methylphenidate—Cardiac disorder—Epirubicin—bone cancer	0.00109	0.00109	CcSEcCtD
Methylphenidate—Rhinitis—Doxorubicin—bone cancer	0.00109	0.00109	CcSEcCtD
Methylphenidate—Haemorrhage—Doxorubicin—bone cancer	0.00109	0.00109	CcSEcCtD
Methylphenidate—Pharyngitis—Doxorubicin—bone cancer	0.00108	0.00108	CcSEcCtD
Methylphenidate—Urinary tract disorder—Doxorubicin—bone cancer	0.00107	0.00107	CcSEcCtD
Methylphenidate—Connective tissue disorder—Doxorubicin—bone cancer	0.00107	0.00107	CcSEcCtD
Methylphenidate—Angiopathy—Epirubicin—bone cancer	0.00106	0.00106	CcSEcCtD
Methylphenidate—Urethral disorder—Doxorubicin—bone cancer	0.00106	0.00106	CcSEcCtD
Methylphenidate—Immune system disorder—Epirubicin—bone cancer	0.00106	0.00106	CcSEcCtD
Methylphenidate—Mediastinal disorder—Epirubicin—bone cancer	0.00106	0.00106	CcSEcCtD
Methylphenidate—Back pain—Methotrexate—bone cancer	0.00106	0.00106	CcSEcCtD
Methylphenidate—Chills—Epirubicin—bone cancer	0.00105	0.00105	CcSEcCtD
Methylphenidate—Arrhythmia—Epirubicin—bone cancer	0.00105	0.00105	CcSEcCtD
Methylphenidate—Visual impairment—Doxorubicin—bone cancer	0.00105	0.00105	CcSEcCtD
Methylphenidate—Alopecia—Epirubicin—bone cancer	0.00104	0.00104	CcSEcCtD
Methylphenidate—Vomiting—Cisplatin—bone cancer	0.00103	0.00103	CcSEcCtD
Methylphenidate—Vision blurred—Methotrexate—bone cancer	0.00103	0.00103	CcSEcCtD
Methylphenidate—Mental disorder—Epirubicin—bone cancer	0.00103	0.00103	CcSEcCtD
Methylphenidate—Erythema multiforme—Doxorubicin—bone cancer	0.00103	0.00103	CcSEcCtD
Methylphenidate—Rash—Cisplatin—bone cancer	0.00102	0.00102	CcSEcCtD
Methylphenidate—Dermatitis—Cisplatin—bone cancer	0.00102	0.00102	CcSEcCtD
Methylphenidate—Malnutrition—Epirubicin—bone cancer	0.00102	0.00102	CcSEcCtD
Methylphenidate—Erythema—Epirubicin—bone cancer	0.00102	0.00102	CcSEcCtD
Methylphenidate—Eye disorder—Doxorubicin—bone cancer	0.00101	0.00101	CcSEcCtD
Methylphenidate—Ill-defined disorder—Methotrexate—bone cancer	0.00101	0.00101	CcSEcCtD
Methylphenidate—Anaemia—Methotrexate—bone cancer	0.00101	0.00101	CcSEcCtD
Methylphenidate—Flushing—Doxorubicin—bone cancer	0.00101	0.00101	CcSEcCtD
Methylphenidate—Cardiac disorder—Doxorubicin—bone cancer	0.00101	0.00101	CcSEcCtD
Methylphenidate—Tension—Epirubicin—bone cancer	0.001	0.001	CcSEcCtD
Methylphenidate—Nervousness—Epirubicin—bone cancer	0.000992	0.000992	CcSEcCtD
Methylphenidate—Back pain—Epirubicin—bone cancer	0.000988	0.000988	CcSEcCtD
Methylphenidate—Angiopathy—Doxorubicin—bone cancer	0.000985	0.000985	CcSEcCtD
Methylphenidate—Malaise—Methotrexate—bone cancer	0.000984	0.000984	CcSEcCtD
Methylphenidate—Muscle spasms—Epirubicin—bone cancer	0.000982	0.000982	CcSEcCtD
Methylphenidate—Immune system disorder—Doxorubicin—bone cancer	0.00098	0.00098	CcSEcCtD
Methylphenidate—Vertigo—Methotrexate—bone cancer	0.00098	0.00098	CcSEcCtD
Methylphenidate—Mediastinal disorder—Doxorubicin—bone cancer	0.000978	0.000978	CcSEcCtD
Methylphenidate—Leukopenia—Methotrexate—bone cancer	0.000977	0.000977	CcSEcCtD
Methylphenidate—Chills—Doxorubicin—bone cancer	0.000974	0.000974	CcSEcCtD
Methylphenidate—Arrhythmia—Doxorubicin—bone cancer	0.00097	0.00097	CcSEcCtD
Methylphenidate—Nausea—Cisplatin—bone cancer	0.000964	0.000964	CcSEcCtD
Methylphenidate—Vision blurred—Epirubicin—bone cancer	0.000962	0.000962	CcSEcCtD
Methylphenidate—Alopecia—Doxorubicin—bone cancer	0.000959	0.000959	CcSEcCtD
Methylphenidate—Cough—Methotrexate—bone cancer	0.000952	0.000952	CcSEcCtD
Methylphenidate—Mental disorder—Doxorubicin—bone cancer	0.000951	0.000951	CcSEcCtD
Methylphenidate—Ill-defined disorder—Epirubicin—bone cancer	0.000947	0.000947	CcSEcCtD
Methylphenidate—Convulsion—Methotrexate—bone cancer	0.000945	0.000945	CcSEcCtD
Methylphenidate—Erythema—Doxorubicin—bone cancer	0.000945	0.000945	CcSEcCtD
Methylphenidate—Malnutrition—Doxorubicin—bone cancer	0.000945	0.000945	CcSEcCtD
Methylphenidate—Anaemia—Epirubicin—bone cancer	0.000944	0.000944	CcSEcCtD
Methylphenidate—Agitation—Epirubicin—bone cancer	0.000938	0.000938	CcSEcCtD
Methylphenidate—Arthralgia—Methotrexate—bone cancer	0.000929	0.000929	CcSEcCtD
Methylphenidate—Chest pain—Methotrexate—bone cancer	0.000929	0.000929	CcSEcCtD
Methylphenidate—Myalgia—Methotrexate—bone cancer	0.000929	0.000929	CcSEcCtD
Methylphenidate—Tension—Doxorubicin—bone cancer	0.000927	0.000927	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000922	0.000922	CcSEcCtD
Methylphenidate—Malaise—Epirubicin—bone cancer	0.000921	0.000921	CcSEcCtD
Methylphenidate—Discomfort—Methotrexate—bone cancer	0.000918	0.000918	CcSEcCtD
Methylphenidate—Nervousness—Doxorubicin—bone cancer	0.000918	0.000918	CcSEcCtD
Methylphenidate—Vertigo—Epirubicin—bone cancer	0.000917	0.000917	CcSEcCtD
Methylphenidate—Syncope—Epirubicin—bone cancer	0.000916	0.000916	CcSEcCtD
Methylphenidate—Leukopenia—Epirubicin—bone cancer	0.000914	0.000914	CcSEcCtD
Methylphenidate—Back pain—Doxorubicin—bone cancer	0.000914	0.000914	CcSEcCtD
Methylphenidate—Muscle spasms—Doxorubicin—bone cancer	0.000908	0.000908	CcSEcCtD
Methylphenidate—Palpitations—Epirubicin—bone cancer	0.000902	0.000902	CcSEcCtD
Methylphenidate—Confusional state—Methotrexate—bone cancer	0.000898	0.000898	CcSEcCtD
Methylphenidate—Loss of consciousness—Epirubicin—bone cancer	0.000897	0.000897	CcSEcCtD
Methylphenidate—Cough—Epirubicin—bone cancer	0.000891	0.000891	CcSEcCtD
Methylphenidate—Anaphylactic shock—Methotrexate—bone cancer	0.00089	0.00089	CcSEcCtD
Methylphenidate—Vision blurred—Doxorubicin—bone cancer	0.00089	0.00089	CcSEcCtD
Methylphenidate—Convulsion—Epirubicin—bone cancer	0.000885	0.000885	CcSEcCtD
Methylphenidate—Infection—Methotrexate—bone cancer	0.000885	0.000885	CcSEcCtD
Methylphenidate—Hypertension—Epirubicin—bone cancer	0.000882	0.000882	CcSEcCtD
Methylphenidate—Ill-defined disorder—Doxorubicin—bone cancer	0.000877	0.000877	CcSEcCtD
Methylphenidate—Nervous system disorder—Methotrexate—bone cancer	0.000873	0.000873	CcSEcCtD
Methylphenidate—Anaemia—Doxorubicin—bone cancer	0.000873	0.000873	CcSEcCtD
Methylphenidate—Thrombocytopenia—Methotrexate—bone cancer	0.000872	0.000872	CcSEcCtD
Methylphenidate—Chest pain—Epirubicin—bone cancer	0.000869	0.000869	CcSEcCtD
Methylphenidate—Arthralgia—Epirubicin—bone cancer	0.000869	0.000869	CcSEcCtD
Methylphenidate—Myalgia—Epirubicin—bone cancer	0.000869	0.000869	CcSEcCtD
Methylphenidate—Agitation—Doxorubicin—bone cancer	0.000868	0.000868	CcSEcCtD
Methylphenidate—Anxiety—Epirubicin—bone cancer	0.000866	0.000866	CcSEcCtD
Methylphenidate—Skin disorder—Methotrexate—bone cancer	0.000865	0.000865	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000863	0.000863	CcSEcCtD
Methylphenidate—Hyperhidrosis—Methotrexate—bone cancer	0.000861	0.000861	CcSEcCtD
Methylphenidate—Discomfort—Epirubicin—bone cancer	0.000859	0.000859	CcSEcCtD
Methylphenidate—Malaise—Doxorubicin—bone cancer	0.000852	0.000852	CcSEcCtD
Methylphenidate—Dry mouth—Epirubicin—bone cancer	0.00085	0.00085	CcSEcCtD
Methylphenidate—Vertigo—Doxorubicin—bone cancer	0.000849	0.000849	CcSEcCtD
Methylphenidate—Anorexia—Methotrexate—bone cancer	0.000849	0.000849	CcSEcCtD
Methylphenidate—Syncope—Doxorubicin—bone cancer	0.000847	0.000847	CcSEcCtD
Methylphenidate—Leukopenia—Doxorubicin—bone cancer	0.000846	0.000846	CcSEcCtD
Methylphenidate—Confusional state—Epirubicin—bone cancer	0.00084	0.00084	CcSEcCtD
Methylphenidate—Palpitations—Doxorubicin—bone cancer	0.000835	0.000835	CcSEcCtD
Methylphenidate—Anaphylactic shock—Epirubicin—bone cancer	0.000833	0.000833	CcSEcCtD
Methylphenidate—Oedema—Epirubicin—bone cancer	0.000833	0.000833	CcSEcCtD
Methylphenidate—Loss of consciousness—Doxorubicin—bone cancer	0.00083	0.00083	CcSEcCtD
Methylphenidate—Infection—Epirubicin—bone cancer	0.000828	0.000828	CcSEcCtD
Methylphenidate—Cough—Doxorubicin—bone cancer	0.000824	0.000824	CcSEcCtD
Methylphenidate—Shock—Epirubicin—bone cancer	0.00082	0.00082	CcSEcCtD
Methylphenidate—Convulsion—Doxorubicin—bone cancer	0.000819	0.000819	CcSEcCtD
Methylphenidate—Nervous system disorder—Epirubicin—bone cancer	0.000817	0.000817	CcSEcCtD
Methylphenidate—Thrombocytopenia—Epirubicin—bone cancer	0.000816	0.000816	CcSEcCtD
Methylphenidate—Hypertension—Doxorubicin—bone cancer	0.000816	0.000816	CcSEcCtD
Methylphenidate—Tachycardia—Epirubicin—bone cancer	0.000813	0.000813	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000811	0.000811	CcSEcCtD
Methylphenidate—Skin disorder—Epirubicin—bone cancer	0.000809	0.000809	CcSEcCtD
Methylphenidate—Hyperhidrosis—Epirubicin—bone cancer	0.000806	0.000806	CcSEcCtD
Methylphenidate—Insomnia—Methotrexate—bone cancer	0.000805	0.000805	CcSEcCtD
Methylphenidate—Arthralgia—Doxorubicin—bone cancer	0.000804	0.000804	CcSEcCtD
Methylphenidate—Chest pain—Doxorubicin—bone cancer	0.000804	0.000804	CcSEcCtD
Methylphenidate—Myalgia—Doxorubicin—bone cancer	0.000804	0.000804	CcSEcCtD
Methylphenidate—Anxiety—Doxorubicin—bone cancer	0.000802	0.000802	CcSEcCtD
Methylphenidate—Paraesthesia—Methotrexate—bone cancer	0.0008	0.0008	CcSEcCtD
Methylphenidate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000799	0.000799	CcSEcCtD
Methylphenidate—Discomfort—Doxorubicin—bone cancer	0.000795	0.000795	CcSEcCtD
Methylphenidate—Anorexia—Epirubicin—bone cancer	0.000794	0.000794	CcSEcCtD
Methylphenidate—Dyspnoea—Methotrexate—bone cancer	0.000794	0.000794	CcSEcCtD
Methylphenidate—Somnolence—Methotrexate—bone cancer	0.000792	0.000792	CcSEcCtD
Methylphenidate—Dry mouth—Doxorubicin—bone cancer	0.000787	0.000787	CcSEcCtD
Methylphenidate—Dyspepsia—Methotrexate—bone cancer	0.000784	0.000784	CcSEcCtD
Methylphenidate—Confusional state—Doxorubicin—bone cancer	0.000777	0.000777	CcSEcCtD
Methylphenidate—Decreased appetite—Methotrexate—bone cancer	0.000774	0.000774	CcSEcCtD
Methylphenidate—Anaphylactic shock—Doxorubicin—bone cancer	0.000771	0.000771	CcSEcCtD
Methylphenidate—Oedema—Doxorubicin—bone cancer	0.000771	0.000771	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Methotrexate—bone cancer	0.000769	0.000769	CcSEcCtD
Methylphenidate—Fatigue—Methotrexate—bone cancer	0.000768	0.000768	CcSEcCtD
Methylphenidate—Infection—Doxorubicin—bone cancer	0.000766	0.000766	CcSEcCtD
Methylphenidate—Pain—Methotrexate—bone cancer	0.000761	0.000761	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000759	0.000759	CcSEcCtD
Methylphenidate—Shock—Doxorubicin—bone cancer	0.000759	0.000759	CcSEcCtD
Methylphenidate—Nervous system disorder—Doxorubicin—bone cancer	0.000756	0.000756	CcSEcCtD
Methylphenidate—Thrombocytopenia—Doxorubicin—bone cancer	0.000755	0.000755	CcSEcCtD
Methylphenidate—Insomnia—Epirubicin—bone cancer	0.000754	0.000754	CcSEcCtD
Methylphenidate—Tachycardia—Doxorubicin—bone cancer	0.000753	0.000753	CcSEcCtD
Methylphenidate—Skin disorder—Doxorubicin—bone cancer	0.000749	0.000749	CcSEcCtD
Methylphenidate—Paraesthesia—Epirubicin—bone cancer	0.000748	0.000748	CcSEcCtD
Methylphenidate—Hyperhidrosis—Doxorubicin—bone cancer	0.000745	0.000745	CcSEcCtD
Methylphenidate—Dyspnoea—Epirubicin—bone cancer	0.000743	0.000743	CcSEcCtD
Methylphenidate—Somnolence—Epirubicin—bone cancer	0.000741	0.000741	CcSEcCtD
Methylphenidate—Anorexia—Doxorubicin—bone cancer	0.000735	0.000735	CcSEcCtD
Methylphenidate—Feeling abnormal—Methotrexate—bone cancer	0.000734	0.000734	CcSEcCtD
Methylphenidate—Dyspepsia—Epirubicin—bone cancer	0.000734	0.000734	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Methotrexate—bone cancer	0.000728	0.000728	CcSEcCtD
Methylphenidate—Decreased appetite—Epirubicin—bone cancer	0.000724	0.000724	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Epirubicin—bone cancer	0.000719	0.000719	CcSEcCtD
Methylphenidate—Fatigue—Epirubicin—bone cancer	0.000718	0.000718	CcSEcCtD
Methylphenidate—Pain—Epirubicin—bone cancer	0.000713	0.000713	CcSEcCtD
Methylphenidate—Constipation—Epirubicin—bone cancer	0.000713	0.000713	CcSEcCtD
Methylphenidate—Urticaria—Methotrexate—bone cancer	0.000707	0.000707	CcSEcCtD
Methylphenidate—Abdominal pain—Methotrexate—bone cancer	0.000704	0.000704	CcSEcCtD
Methylphenidate—Body temperature increased—Methotrexate—bone cancer	0.000704	0.000704	CcSEcCtD
Methylphenidate—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000702	0.000702	CcSEcCtD
Methylphenidate—Insomnia—Doxorubicin—bone cancer	0.000697	0.000697	CcSEcCtD
Methylphenidate—Paraesthesia—Doxorubicin—bone cancer	0.000692	0.000692	CcSEcCtD
Methylphenidate—Dyspnoea—Doxorubicin—bone cancer	0.000687	0.000687	CcSEcCtD
Methylphenidate—Feeling abnormal—Epirubicin—bone cancer	0.000687	0.000687	CcSEcCtD
Methylphenidate—Somnolence—Doxorubicin—bone cancer	0.000685	0.000685	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Epirubicin—bone cancer	0.000681	0.000681	CcSEcCtD
Methylphenidate—Dyspepsia—Doxorubicin—bone cancer	0.000679	0.000679	CcSEcCtD
Methylphenidate—Decreased appetite—Doxorubicin—bone cancer	0.00067	0.00067	CcSEcCtD
Methylphenidate—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000666	0.000666	CcSEcCtD
Methylphenidate—Fatigue—Doxorubicin—bone cancer	0.000665	0.000665	CcSEcCtD
Methylphenidate—Urticaria—Epirubicin—bone cancer	0.000662	0.000662	CcSEcCtD
Methylphenidate—Pain—Doxorubicin—bone cancer	0.000659	0.000659	CcSEcCtD
Methylphenidate—Constipation—Doxorubicin—bone cancer	0.000659	0.000659	CcSEcCtD
Methylphenidate—Body temperature increased—Epirubicin—bone cancer	0.000659	0.000659	CcSEcCtD
Methylphenidate—Abdominal pain—Epirubicin—bone cancer	0.000659	0.000659	CcSEcCtD
Methylphenidate—Hypersensitivity—Methotrexate—bone cancer	0.000656	0.000656	CcSEcCtD
Methylphenidate—Asthenia—Methotrexate—bone cancer	0.000639	0.000639	CcSEcCtD
Methylphenidate—Feeling abnormal—Doxorubicin—bone cancer	0.000635	0.000635	CcSEcCtD
Methylphenidate—Gastrointestinal pain—Doxorubicin—bone cancer	0.00063	0.00063	CcSEcCtD
Methylphenidate—Pruritus—Methotrexate—bone cancer	0.00063	0.00063	CcSEcCtD
Methylphenidate—Hypersensitivity—Epirubicin—bone cancer	0.000614	0.000614	CcSEcCtD
Methylphenidate—Urticaria—Doxorubicin—bone cancer	0.000613	0.000613	CcSEcCtD
Methylphenidate—Abdominal pain—Doxorubicin—bone cancer	0.00061	0.00061	CcSEcCtD
Methylphenidate—Body temperature increased—Doxorubicin—bone cancer	0.00061	0.00061	CcSEcCtD
Methylphenidate—Diarrhoea—Methotrexate—bone cancer	0.000609	0.000609	CcSEcCtD
Methylphenidate—Asthenia—Epirubicin—bone cancer	0.000598	0.000598	CcSEcCtD
Methylphenidate—Pruritus—Epirubicin—bone cancer	0.00059	0.00059	CcSEcCtD
Methylphenidate—Dizziness—Methotrexate—bone cancer	0.000589	0.000589	CcSEcCtD
Methylphenidate—Diarrhoea—Epirubicin—bone cancer	0.00057	0.00057	CcSEcCtD
Methylphenidate—Hypersensitivity—Doxorubicin—bone cancer	0.000568	0.000568	CcSEcCtD
Methylphenidate—Vomiting—Methotrexate—bone cancer	0.000566	0.000566	CcSEcCtD
Methylphenidate—Rash—Methotrexate—bone cancer	0.000561	0.000561	CcSEcCtD
Methylphenidate—Dermatitis—Methotrexate—bone cancer	0.000561	0.000561	CcSEcCtD
Methylphenidate—Headache—Methotrexate—bone cancer	0.000558	0.000558	CcSEcCtD
Methylphenidate—Asthenia—Doxorubicin—bone cancer	0.000553	0.000553	CcSEcCtD
Methylphenidate—Dizziness—Epirubicin—bone cancer	0.000551	0.000551	CcSEcCtD
Methylphenidate—Pruritus—Doxorubicin—bone cancer	0.000546	0.000546	CcSEcCtD
Methylphenidate—Vomiting—Epirubicin—bone cancer	0.00053	0.00053	CcSEcCtD
Methylphenidate—Nausea—Methotrexate—bone cancer	0.000529	0.000529	CcSEcCtD
Methylphenidate—Diarrhoea—Doxorubicin—bone cancer	0.000528	0.000528	CcSEcCtD
Methylphenidate—Rash—Epirubicin—bone cancer	0.000525	0.000525	CcSEcCtD
Methylphenidate—Dermatitis—Epirubicin—bone cancer	0.000525	0.000525	CcSEcCtD
Methylphenidate—Headache—Epirubicin—bone cancer	0.000522	0.000522	CcSEcCtD
Methylphenidate—Dizziness—Doxorubicin—bone cancer	0.00051	0.00051	CcSEcCtD
Methylphenidate—Nausea—Epirubicin—bone cancer	0.000495	0.000495	CcSEcCtD
Methylphenidate—Vomiting—Doxorubicin—bone cancer	0.00049	0.00049	CcSEcCtD
Methylphenidate—Rash—Doxorubicin—bone cancer	0.000486	0.000486	CcSEcCtD
Methylphenidate—Dermatitis—Doxorubicin—bone cancer	0.000486	0.000486	CcSEcCtD
Methylphenidate—Headache—Doxorubicin—bone cancer	0.000483	0.000483	CcSEcCtD
Methylphenidate—Nausea—Doxorubicin—bone cancer	0.000458	0.000458	CcSEcCtD
